Hepatitis Monthly

Published by: Kowsar

Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response

Tatiana Kuznetsova 1 , Tatjana Tallo 1 , 2 , Vadim Brjalin 3 , * , Irina Reshetnjak 1 , Riina Salupere 4 , Ljudmilla Priimagi 1 , Olga Katargina 1 , Maria Smirnova 5 , Juris Jansons 6 and Valentina Tefanova 1
Authors Information
1 Department of Virology, National Institute for Health Development, Tallinn, Estonia
2 Department of Diagnostics and Vaccine, Unit for Molecular Typing, Swedish Institute for Communicable Disease Control, Stockholm, Sweden
3 Department of Internal Medicine, West-Tallinn Central Hospital, Tallinn, Estonia
4 Department of Internal Medicine, University of Tartu, Tartu, Estonia
5 Department of Hemorrhagic Fevers and Pilot Projects, Federal State Budgetary Institution “Chumakov Institute of Poliomyelitis and Viral Encephalitides” of RAMS, Moscow, Russia
6 Protein Engineering Department, Latvian Biomedical Research and Study Centre, Riga, Latvia
Article information
  • Hepatitis Monthly: December 2013, 13 (12); e14481
  • Published Online: December 14, 2013
  • Article Type: Research Article
  • Received: August 28, 2013
  • Revised: September 29, 2013
  • Accepted: November 1, 2013
  • DOI: 10.5812/hepatmon.14481

To Cite: Kuznetsova T, Tallo T, Brjalin V, Reshetnjak I, Salupere R, et al. Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response, Hepat Mon. 2013 ;13(12):e14481. doi: 10.5812/hepatmon.14481.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41[PubMed]
  • 2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 3. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012; 19(7): 449-64[DOI][PubMed]
  • 4. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 5. Saludes V, Bracho MA, Valero O, Ardevol M, Planas R, Gonzalez-Candelas F, et al. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One. 2010; 5(11)[DOI][PubMed]
  • 6. Shiffman ML. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. Curr Gastroenterol Rep. 2006; 8(1): 46-52[PubMed]
  • 7. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005; 43(3): 425-33[DOI][PubMed]
  • 8. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2): 124-34[DOI][PubMed]
  • 9. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, et al. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol. 2007; 79(4): 374-82[DOI][PubMed]
  • 10. Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, et al. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J Med Virol. 2009; 81(12): 2021-8[DOI][PubMed]
  • 11. Noguchi T, Tamori A, Ogura N, Hori Y, Ikeda S, Nishiguchi S. Investigation of interferon-alpha response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients. J Interferon Cytokine Res. 2011; 31(8): 589-99[DOI][PubMed]
  • 12. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008; 48(1): 38-47[DOI][PubMed]
  • 13. Munoz de Rueda P, Casado J, Paton R, Quintero D, Palacios A, Gila A, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol. 2008; 82(13): 6644-53[DOI][PubMed]
  • 14. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334(2): 77-81[DOI][PubMed]
  • 15. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci. 2002; 47(6): 1195-205[PubMed]
  • 16. Kmieciak D, Kruszyna L, Migdalski P, Lacinski M, Juszczyk J, Trzeciak WH. Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment. Jpn J Infect Dis. 2006; 59(2): 92-9[PubMed]
  • 17. Veillon P, Payan C, Gaudy C, Goudeau A, Lunel F. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin]. Pathol Biol (Paris). 2004; 52(9): 505-10[DOI][PubMed]
  • 18. Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, et al. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B. J Med Virol. 2007; 79(1): 35-40[DOI][PubMed]
  • 19. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002; 76(21): 11079-90[PubMed]
  • 20. Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis? J Viral Hepat. 2002; 9(5): 360-9[PubMed]
  • 21. Zhou XM, Chan PK, Tam JS. Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population. World J Gastroenterol. 2011; 17(48): 5317-23[DOI][PubMed]
  • 22. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut. 2004; 53(9): 1345-51[DOI][PubMed]
  • 23. Brillet R, Penin F, Hezode C, Chouteau P, Dhumeaux D, Pawlotsky JM. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. J Infect Dis. 2007; 195(3): 432-41[DOI][PubMed]
  • 24. Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, et al. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol. 2010; 25(6): 1072-8[DOI][PubMed]
  • 25. Puig-Basagoiti F, Saiz JC, Forns X, Ampurdanes S, Gimenez-Barcons M, Franco S, et al. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J Med Virol. 2001; 65(1): 35-44[PubMed]
  • 26. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, et al. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat. 2006; 13(9): 582-90[DOI][PubMed]
  • 27. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A. 2002; 99(5): 3081-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader